Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
Status:
Completed
Trial end date:
2005-09-28
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to determine if Serostim® 4 mg administered daily for
12 weeks as treatment for the abnormal fat accumulation and distribution associated with
HIV-associated Adipose Redistribution Syndrome (HARS) reduces Visceral Adipose Tissue (VAT,
measured by CT scan) more effectively than placebo.